229
Participants
Start Date
November 30, 2011
Primary Completion Date
June 30, 2018
Study Completion Date
April 11, 2022
Milestone 1: Targeted chemotherapy prior to surgery
The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
Milestone 2: Chemoradiotherapy (cXRT)
A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Milestone 3: Targeted chemotherapy prior to surgery
The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
Milestone 3: Chemoradiotherapy (cXRT)
A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery
A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
Milestone 4: Chemoradiotherapy (cXRT)
A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Milestone 5: Targeted chemotherapy after surgery
The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
Milestone 5: Chemoradiotherapy (cXRT)
A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Milestone 6: Gemcitabine after surgery
Chemotherapy treatment with Gemcitabine.
Milestone 6: Chemoradiotherapy (cXRT)
A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Milestone 7: Chemoradiotherapy (cXRT)
A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Milestone 8: Targeted chemotherapy after surgery
The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
Milestone 9: Gemcitabine after surgery
Chemotherapy treatment with Gemcitabine.
Milestone 10: No additional therapy after surgery
The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
University of Cincinnati Cancer Center, Cincinnati
Froedtert and The Medical College of Wisconsin, Milwaukee
University of Cincinnati
OTHER
Medical College of Wisconsin
OTHER